Patient Characteristics
| Characteristic | All | Responders | Nonresponders | P |
| Age (y) | 57.8 ± 12.1 | 59.0 ± 10.7 | 54.9 ± 17.1 | 0.64 |
| Sex | 0.28 | |||
| Male | 20 | 14 | 6 | |
| Female | 11 | 9 | 1 | |
| Previous therapies (e.g., surgery, chemotherapy) | 1.8 | 1.4 ± 1.2 | 2.6 ± 2.0 | 0.15 |
| Pretherapeutic SUVmax | 28.5 ± 15.5 | 33.0 ± 16.1 | 19.1 ± 7.1 | 0.01 |
| TTP (mo) | Not reached | Not reached | 6 | <0.001 |
| Clinical symptoms | 16 | 10 | 6 | 0.2 |
| Chromogranin A | ||||
| Elevated | 21 | 15 | 6 | 0.28 |
| Pretherapeutic value | 5,306 | 7,420 ± 25,206 | 2,189 ± 4,178 | 0.73 |
| NSE | ||||
| Elevated | 19 | 13 | 6 | 0.95 |
| Pretherapeutic value | 39.7 | 23.9 ± 15.2 | 24.0 ± 11.3 | 0.97 |
| Time (wk) between PRRT and… | ||||
| Pretherapeutic PET | 7.1 ± 3.5 | 7.0 ± 3.5 | 7.1 ± 4.1 | 0.77 |
| Posttherapeutic PET | 13.2 ± 2.3 | 13.4 ± 2.3 | 13.1 ± 2.5 | 0.44 |
| Octreotide treatment | 5 | 3 | 2 | 0.78 |
Two of the 33 patients had history of splenectomy. Data are n or mean ± SD. Mann–Whitney U test was used for statistical analyses between responders (decline of ΔSUVT/S) and nonresponders (increase of ΔSUVT/S).